series-a
Stage
2
Investors
About
Sigyn Therapeutics develops CardioDialysis™, a medical device designed to reduce circulating inflammatory molecules and cholesterol-transporting lipoproteins to lower the risk of major adverse cardiovascular events. The device leverages existing dialysis infrastructure for potential broad-scale deployment in U.S. dialysis clinics.
Explore Sigyn Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.